Junior Tchamadeu talks about the development in his own game, his love of getting forward and the changing room pair who want to help him as much as possible ...
Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...
The United Kingdom’s Competition and Markets Authority (CMA) has approved the proposed merger of American Express Global ...
Jim O’Neill, President Trump’s pick to be second-in-command at HHS, has a history of working with vaccine companies and other ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Stoke will welcome promotion-chasing Sheffield United to the bet365 Stadium on Friday, April 25 with an 8pm kick-off. It will be a reunion with familiar faces including former Stoke strikers Tyrese ...
We answer your questions about the expiration of the contract between Blue Cross Blue Shield of Texas and Southwestern Health ...
Previous skepticism turns to optimism as the first clinical trials for transplantation with genetically edited pig kidneys ...
Shares of early-stage biotech stocks, including Biohaven ( BHVN -6.50%), Recursion Pharmaceuticals ( RXRX -7.37%), and CRISPR ...
Axsome Therapeutics said it's dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive ...
As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and mass layoffs throughout the FDA raise concerns about the agency’s ability to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback